ATNX News and Press, Athenex Inc. From 01/25/21

BUFFALO, N.Y., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its CEO and Board...

Gainers: [[EXPR]] +44%. [[SMTS]] +12.9%. [[MBI]] +12.7%. [[JE]] +12.5%. [[WPF]] +6.3%.Losers: [[ATNX]] -7.6%. [[CLPS]] -4.3%. [[DWSN]] -4.3%. [[RNWK]] -4.2%. [[ENSV]] -2.4%. For further details see: JE, EXPR, ATNX and ENSV among after-hours movers

The following slide deck was published by Athenex, Inc. in conjunction with this event. For further details see: Athenex (ATNX) Presents at J.P. Morgan Healthcare Conference 2021 - Slideshow

BUFFALO, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman,...

BUFFALO, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it will participate in the ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Prevail Therapeutics (PRVL) +84% on being acquired by Lilly for ~$1.04B.OncoCyte Corporation (OCX) +63% after company enters agreement with Burning Rock Biotech.Anavex Life Sciences (AVXL) +40% as it's blarcamesine successful in mid-stage rett syndrome study.Mid-Con Energy Part...

Athenex (ATNX) jumps 10% premarket on after FDA approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis ((AK)) on the face or scalp.Klisyri is the first FDA approved branded proprietary product for Athenex and will be launched in partnership with Almirall (LBT...

Klisyri ® is the first FDA approved proprietary product for Athenex First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by ...

Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis EXTON, Pa. , Dec. 15, 2020 /PRNewswire/ -- Almirall, S.A. (BME:ALM) , a global biopharmaceutical company focused on skin health, announc...